APA (7th ed.) Citation

NJ, C., L, M., L, H., F, M., N, W., H, Z., . . . SE, C. (2017). Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity. Oncotarget, 8(41), 69219. https://doi.org/10.18632/oncotarget.18215

Chicago Style (17th ed.) Citation

NJ, Curtis, et al. "Pre-clinical Pharmacology of AZD3965, a Selective Inhibitor of MCT1: DLBCL, NHL and Burkitt's Lymphoma Anti-tumor Activity." Oncotarget 8, no. 41 (2017): 69219. https://doi.org/10.18632/oncotarget.18215.

MLA (9th ed.) Citation

NJ, Curtis, et al. "Pre-clinical Pharmacology of AZD3965, a Selective Inhibitor of MCT1: DLBCL, NHL and Burkitt's Lymphoma Anti-tumor Activity." Oncotarget, vol. 8, no. 41, 2017, p. 69219, https://doi.org/10.18632/oncotarget.18215.